Atrasentan

A pyrrolidine and benzodioxole derivative that acts a RECEPTOR, ENDOTHELIN A antagonist. It has therapeutic potential as an antineoplastic agent and for the treatment of DIABETIC NEPHROPATHIES.

Also Known As:

(11C)ABT-627; 2-(4-Methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(((dibutylamino)carbonyl)methyl)pyrrolidine-3-carboxylic acid; A 127722; A 147627; A-127722; A-127722.5; A-147627; ABT 627; ABT-627; Atrasentan Hydrochloride; Xinlay; A 127722.5; A127722; A127722.5; A147627; ABT627; 3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-, (2R,3R,4S)-

Networked: 239 relevant articles (27 outcomes, 86 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - Atrasentan: 239
  - Dioxoles
    - Benzodioxoles: 3
      - Atrasentan: 239
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzodioxoles: 3
      - Atrasentan: 239

Experts

1.	de Zeeuw, Dick: 17 articles (01/2022 - 05/2014)
2.	Parving, Hans-Henrik: 16 articles (01/2022 - 05/2014)
3.	Heerspink, Hiddo J L: 15 articles (01/2022 - 01/2017)
4.	Correa-Rotter, Ricardo: 14 articles (01/2022 - 05/2014)
5.	Makino, Hirofumi: 13 articles (01/2022 - 05/2014)
6.	Perkovic, Vlado: 13 articles (01/2022 - 05/2014)
7.	Bagnato, Anna: 13 articles (01/2007 - 08/2002)
8.	Kohan, Donald E: 12 articles (01/2022 - 04/2011)
9.	Nelson, Joel B: 11 articles (01/2009 - 04/2002)
10.	Carducci, Michael A: 10 articles (01/2017 - 04/2002)

Related Diseases

1.	Albuminuria 11/01/2021 - "Accordingly, the predictive effect of early albuminuria changes during atrasentan was eliminated after placebo correction, leading to a consistent relative risk reduction for the primary kidney outcome with atrasentan compared with placebo, irrespective of the initial UACR response. " 01/01/2023 - "RADAR trial (Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With AtRasentan): NCT01356849. " 11/01/2021 - "However, the variable trajectory in UACR with placebo, aspects of the trial design, day-to-day variability in albuminuria, and potential long-lasting effects of atrasentan may have contributed." 05/01/2016 - "The ongoing hard outcome trial (SONAR) in type 2 diabetic patients with >30% albuminuria reduction to atrasentan will allow us to assess the validity of these predictions." 09/04/2015 - "In the Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan/JAPAN trials, atrasentan-associated fluid retention was more likely in patients with diabetes and nephropathy who had lower eGFR or received a higher dose of atrasentan. "
2.	Prostatic Neoplasms (Prostate Cancer) 05/01/2006 - "Atrasentan clinical trials demonstrated a statistically significant difference in the prostate cancer-specific QOL in favor of atrasentan (p=.032) and an increased quality-adjusted time to progression in men with HRPC. " 05/27/2004 - "Preliminary data from clinical trials investigating atrasentan in patients with prostate cancer are encouraging. " 02/01/2003 - "Preliminary results from clinical trials, such as those with atrasentan--an ET(A)-receptor antagonist--in prostate cancer, are encouraging. " 01/15/2014 - "Atrasentan of no benefit to men with metastatic prostate cancer." 03/01/2010 - "The clinical investigation of an orally bioavailable ET antagonist, atrasentan, in prostate cancer, is encouraging. "
3.	Diabetic Nephropathies (Diabetic Nephropathy) 01/01/2021 - "The phase 3 SONAR trial demonstrated a significant reduction in clinically relevant kidney outcomes for patients with diabetic kidney disease (DKD) after long-term treatment with the ERA, atrasentan, in addition to blockade of the renin-angiotensin-aldosterone system. " 10/13/2023 - "Further studies could focus on the effect of the Atrasentan on the diabetic nephropathy management,which will shed light on the treatment of diabetic nephropathy." 10/13/2023 - "The machine searches eight databases to find studies examining the impact of Atrasentan in people with diabetic nephropathy both domestically and overseas. " 01/01/2023 - "SONAR trial (The Study Of Diabetic Nephropathy With AtRasentan) NCT01858532." 01/01/2022 - "(Study Of Diabetic Nephropathy With Atrasentan [SONAR]; NCT01858532)."
4.	Ischemia 01/25/2005 - "Postischemic cardiac dysfunction and NE overflow in the heart of ET(B) receptor-deficient homozygous (sl/sl) rats were highly observed compared with cases in wild-type rats, and exaggerated responses to ischemia/reperfusion in sl/sl rats were abolished by ABT-627 treatment. " 05/01/1998 - "A-127722 administered simultaneously with L-NNA completely prevented the increase in proteinuria (39+/-8 mg/d) and glomerular ischemia. " 07/01/2012 - "On the other hand, the beneficial effects of ABT-627 (1 and 3 μM) on NE overflow (carrier-mediated release) and cardiac dysfunction were also observed in 40-minute ischemia, whereas those were not improved by treatment with candesartan (10 and 100 nM and 1 μM). " 10/01/2013 - "Pre- and post-ischemia or just postischemic treatment with Atrasentan conferred dramatic protective effects such as decreased tubule/microvascular injury, normalized tissue lactate, and total preservation of renal mass. " 07/01/2012 - "Candesartan (10 and 100 nM) and ABT-627 (3 μM) suppressed excessive NE overflow (exocytotic release) in the coronary effluent from the heart exposed to 20-minute ischemia. "
5.	Neoplasms (Cancer) 11/01/2004 - "on day 1) markedly inhibited HEY tumors, atrasentan was very effective in potentiating this effect, with partial or complete tumor regression. " 07/01/2004 - "This Phase I study sought to determine the toxicity and pharmacokinetics of daily atrasentan in a population of both female and male subjects with advanced malignancies. " 07/01/2004 - "Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies." 08/01/2003 - "After 28 days, patients without objective signs of tumor progression were eligible to continue atrasentan in an extension study. " 04/15/2002 - "This study evaluated the safety, pharmacokinetics, and maximum-tolerated dose of atrasentan in cancer patients. "

Related Drugs and Biologics

1.	Docetaxel (Taxotere)
2.	Avosentan
3.	Lipids
4.	Endothelin A Receptor
5.	Endothelin Receptor Antagonists
6.	A 192621
7.	Bosentan (Tracleer)
8.	Salts
9.	Endothelin Receptors (Endothelin Receptor)
10.	Sodium

Related Therapies and Procedures

1.	Castration
2.	Therapeutics
3.	Oral Administration
4.	Drug Therapy (Chemotherapy)
5.	Nephrectomy